Investigation into XOMA's Board Fiduciary Duties Amid $739M Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy XOMA?
Source: Globenewswire
- Acquisition Context: XOMA Royalty Corporation has announced its acquisition by Ligand Pharmaceuticals for $739 million, highlighting market interest and the potential value of the company.
- Board Investigation: The Schall Law Firm is investigating whether XOMA's board breached fiduciary duties to shareholders, which could impact shareholder rights and corporate governance.
- Shareholder Rights Protection: The firm encourages shareholders to participate in the investigation, aiming to ensure that their legal rights are upheld, reflecting a commitment to governance transparency.
- Legal Consultation Services: Schall Law Firm offers free consultations to help shareholders understand their rights, further promoting accountability within the company's management structure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.970
Low
50.00
Averages
71.00
High
97.00
Current: 41.970
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into XOMA's Board Fiduciary Duties Amid $739M Acquisition
- Acquisition Context: XOMA Royalty Corporation has announced its acquisition by Ligand Pharmaceuticals for $739 million, highlighting market interest and the potential value of the company.
- Board Investigation: The Schall Law Firm is investigating whether XOMA's board breached fiduciary duties to shareholders, which could impact shareholder rights and corporate governance.
- Shareholder Rights Protection: The firm encourages shareholders to participate in the investigation, aiming to ensure that their legal rights are upheld, reflecting a commitment to governance transparency.
- Legal Consultation Services: Schall Law Firm offers free consultations to help shareholders understand their rights, further promoting accountability within the company's management structure.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
Investigation into XOMA Royalty Acquisition
- Investigation Launched: Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation and its board regarding the acquisition proposal by Ligand Pharmaceuticals, indicating significant concerns over transaction compliance.
- Transaction Details Revealed: The acquisition is valued at approximately $739 million, with shareholders set to receive $39.00 per share plus a contingent value right, reflecting the market's potential reaction and the protection of shareholder interests.
- Expected Completion Timeline: The transaction is anticipated to close in the third quarter of 2026, with the clarity of the timeline potentially influencing shareholder confidence and subsequent decision-making.
- Legal Support Information: Rowley Law PLLC has provided contact details for shareholders seeking more information about the investigation, demonstrating the firm's commitment to offering legal support and enhancing representation in complex corporate litigation.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Monteverde Law Firm Investigates XOMA Sale to Ligand Pharmaceuticals
- Shareholder Protection: Monteverde & Associates is investigating the sale of XOMA Royalty Corporation to Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash, aiming to ensure the fairness of the deal and protect shareholder interests.
- Law Firm Recognition: The firm is recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, showcasing its strong capabilities and successful track record in shareholder protection, thereby enhancing its reputation in the legal field.
- Risk-Free Consultation: Monteverde & Associates offers free consultations, allowing shareholders to obtain more information about the transaction without any cost or obligation, reflecting its commitment to client service and responsibility.
- Strategic Location: Headquartered in the Empire State Building in New York City, this national class action securities firm can leverage its geographical advantage to respond quickly to client needs and provide efficient legal services.
See More
Investigation into XOMA's Board Fiduciary Duties Amid $739M Acquisition
- Acquisition Context: XOMA Royalty Corporation has announced its acquisition by Ligand Pharmaceuticals for $739 million, highlighting market interest and the potential value of the company.
- Board Investigation: The Schall Law Firm is investigating whether XOMA's board breached fiduciary duties to shareholders, which could impact shareholder rights and corporate governance.
- Shareholder Rights Protection: The firm encourages shareholders to participate in the investigation, aiming to ensure that their legal rights are upheld, reflecting a commitment to governance transparency.
- Legal Consultation Services: Schall Law Firm offers free consultations to help shareholders understand their rights, further promoting accountability within the company's management structure.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
Investigation into XOMA Royalty Acquisition
- Investigation Launched: Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation and its board regarding the acquisition proposal by Ligand Pharmaceuticals, indicating significant concerns over transaction compliance.
- Transaction Details Revealed: The acquisition is valued at approximately $739 million, with shareholders set to receive $39.00 per share plus a contingent value right, reflecting the market's potential reaction and the protection of shareholder interests.
- Expected Completion Timeline: The transaction is anticipated to close in the third quarter of 2026, with the clarity of the timeline potentially influencing shareholder confidence and subsequent decision-making.
- Legal Support Information: Rowley Law PLLC has provided contact details for shareholders seeking more information about the investigation, demonstrating the firm's commitment to offering legal support and enhancing representation in complex corporate litigation.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Monteverde Law Firm Investigates XOMA Sale to Ligand Pharmaceuticals
- Shareholder Protection: Monteverde & Associates is investigating the sale of XOMA Royalty Corporation to Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash, aiming to ensure the fairness of the deal and protect shareholder interests.
- Law Firm Recognition: The firm is recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, showcasing its strong capabilities and successful track record in shareholder protection, thereby enhancing its reputation in the legal field.
- Risk-Free Consultation: Monteverde & Associates offers free consultations, allowing shareholders to obtain more information about the transaction without any cost or obligation, reflecting its commitment to client service and responsibility.
- Strategic Location: Headquartered in the Empire State Building in New York City, this national class action securities firm can leverage its geographical advantage to respond quickly to client needs and provide efficient legal services.
See More
